PALB2-话题@MedSci

#PALB2#

10篇内容 | 702人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1621439, encodeId=5405162143942, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, objectType=article, longId=723981, objectId=f235e2398163, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f235e2398163, replyNumber=0, likeNumber=0, createdTime=2022-04-12, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f235e2398163, moduleTitle=AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f235e2398163)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621438, encodeId=cb34162143888, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=Genet Med：PALB2和CHEK2 c.1100delC检测在乳腺-卵巢癌中的临床实用性, objectType=article, longId=212796, objectId=912b212e9695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=912b212e9695, replyNumber=0, likeNumber=32, createdTime=2021-06-17, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=912b212e9695, moduleTitle=Genet Med：PALB2和CHEK2 c.1100delC检测在乳腺-卵巢癌中的临床实用性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=912b212e9695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621437, encodeId=83d6162143ebb, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=Br J Cancer：PALB2突变提高前列腺癌的患病风险, objectType=article, longId=211731, objectId=15dc211e3106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15dc211e3106, replyNumber=0, likeNumber=30, createdTime=2021-05-25, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15dc211e3106, moduleTitle=Br J Cancer：PALB2突变提高前列腺癌的患病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15dc211e3106)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621436, encodeId=2ac316214362f, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=Brit J Cancer：PALB2突变与前列腺癌风险和生存率的关系, objectType=article, longId=211507, objectId=7f8321150ea1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8321150ea1, replyNumber=0, likeNumber=34, createdTime=2021-05-20, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8321150ea1, moduleTitle=Brit J Cancer：PALB2突变与前列腺癌风险和生存率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8321150ea1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621435, encodeId=36ca162143596, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, objectType=article, longId=211199, objectId=ffa121119985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffa121119985, replyNumber=0, likeNumber=29, createdTime=2021-05-14, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffa121119985, moduleTitle=JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffa121119985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621434, encodeId=846a16214346d, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益, objectType=article, longId=202809, objectId=253d202809c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=253d202809c6, replyNumber=0, likeNumber=32, createdTime=2020-11-04, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=253d202809c6, moduleTitle=J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=253d202809c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621433, encodeId=cff7162143383, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=J Clin Oncol：与种系PALB2致病变异相关的癌症风险研究 , objectType=article, longId=190176, objectId=5cba1901e631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cba1901e631, replyNumber=0, likeNumber=32, createdTime=2020-03-19, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cba1901e631, moduleTitle=J Clin Oncol：与种系PALB2致病变异相关的癌症风险研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cba1901e631)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621432, encodeId=60581621432af, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, objectType=article, longId=190106, objectId=ce37190106a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce37190106a8, replyNumber=0, likeNumber=33, createdTime=2020-03-18, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce37190106a8, moduleTitle=JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce37190106a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621431, encodeId=1541162143194, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=Cancer：基因测序发现男性乳腺癌的易感基因——PALB2, objectType=article, longId=79121, objectId=fb36e9121b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb36e9121b0, replyNumber=0, likeNumber=0, createdTime=2016-10-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb36e9121b0, moduleTitle=Cancer：基因测序发现男性乳腺癌的易感基因——PALB2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb36e9121b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1621430, encodeId=dc6e162143041, content=<a href='/topic/show?id=8f7d1368929' target=_blank style='color:#2F92EE;'>#PALB2#</a>, objectTitle=Lancet Oncol：PALB2突变的乳腺癌临床结果, objectType=article, longId=50470, objectId=96c1504e00b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c1504e00b, replyNumber=0, likeNumber=29, createdTime=2015-05-10, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c1504e00b, moduleTitle=Lancet Oncol：PALB2突变的乳腺癌临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c1504e00b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PALB2

2020-05-29

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

AACR重磅之PETRA试验：新一代PARP1选择性抑制剂AZD5305在BRCA1/2、PALB2或RAD51C/D突变的患者（pts）中的首次人体试验

2022-04-12

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

Genet Med：PALB2和CHEK2 c.1100delC检测在乳腺-卵巢癌中的临床实用性

2021-06-17

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

Br J Cancer：PALB2突变提高前列腺癌的患病风险

2021-05-25

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

Brit J Cancer：PALB2突变与前列腺癌风险和生存率的关系

2021-05-20

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

JCO：鲁卡帕利可有效治疗携带BRCA1/2或PALB2致病性突变的晚期胰腺癌

2021-05-14

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

J Clin Oncol：携带PALB2胚系突变的乳腺癌患者也可从PARPi治疗中获益

2020-11-04

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

J Clin Oncol：与种系PALB2致病变异相关的癌症风险研究

2020-03-19

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

JCO：veliparib并不能改善BRCA/PALB2基因突变的晚期胰腺癌患者预后

2020-03-18

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

Cancer：基因测序发现男性乳腺癌的易感基因——PALB2

2016-10-02

zhouqu_8 (审核中...)

前往app查看评论内容

#PALB2#

Lancet Oncol：PALB2突变的乳腺癌临床结果

2015-05-10

科室
- - 订阅+
  - 更多科室
工具
服务